An interventional study of 1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure in Birch Pollen Allergy and Healthy Control Subjects, sponsored by Oulu University Hospital. Status unknown at 1 site in Finland. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-23.
Sponsored by Oulu University Hospital · Not applicable, Interventional, and Diagnostic
The purpose of this study is to find out how the provocation of the nose changes breathing style (specifically, frequency and tidal volume changes)
It is intended to clarify on both healthy and birch pollen allergic adults how the provocation of the nose with the birch pollen, dilutant and xylometazoline affect the breathing style (breathing pattern) and how these possible changes could be controlled in the measurement of the breathing with respiratory effort belts. In addition to this, our intention is to clarify the effect of the facial mask on the breathing.
The allergic and control subjects undergo nasal provocation in 2 sessions. The first is done with birch pollen extract (should block the nose in allergic subjects) and the second with xylometazoline (should open the nose).
The mask group undergo similar measurements without nasal exposures.
The second objective of the study is to clarify if there are differences between the allergic and control subjects in the function of the autonomous nervous system during these provocations. This is done with the heart rate variability analysis method.
392 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 25 are open to participants now.
This study's planned enrollment of 30 is below the median of 136 across 356 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Browse Rhinitis, Allergic, Seasonal studies →Oulu University Hospital is the lead sponsor of 39 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Two separate exposure sessions: 1) nasal birch pollen exposure 2) nasal xylometazoline exposure
Biological: 1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure
Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
breathing style
frequence and volume of breathing measured with spirometry and respiratory effort belts
Time frame: continuously during 2 hours
thorax - abdomen relation
relation of the movements of the thorax and abdomen as measured with the respiratory belts
Time frame: continuously during 2 hours
activation of the autonomous nervous system
activity of the autonomous nervous system as measured with heart rate variability
Time frame: continuously during 2 hours
This study is status unknown, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Oulu University Hospital